Publication Type: Poster
-
Predictions of outcomes and benefit of immune checkpoint inhibitor treatment in non-small cell lung cancer require information on both tumor and host biology
-
Validation of the Primary Immune Response (PIR) test in advanced non-small cell lung cancer (NSCLC): blinded retrospective analyses from the POPLAR and OAK trials
-
Clinical Utility of the Nodify XL2® Blood-Based Risk Classifier for Management of Benign Pulmonary Nodules in a Real-World Observational Study
-
Nodule Dilemma: Proteomic Biomarker Discordance with PET Results
-
A Blood-Based Autoantibody Test to Help Identify Likely Malignant Indeterminate Pulmonary Nodules: An opportunity for early diagnosis of lung cancer
-
The role of serum proteomic signature in predicting survival by PD-L1 status in patients with non-small cell lung cancer receiving immunotherapy
-
Turnaround Time and Variant Prevalence of a Blood-based KRAS Test in patients with NSCLC
-
Potential role of serum proteome in predicting immune-related adverse events from immunotherapy in non-small cell lung cancer
-
Longitudinal blood-based proteomic testing in advanced non-small cell lung cancer
-
Old Habits Die Hard: Managing Lung Nodules With Size Alone Is Not Sufficient